Roche Reports Result of Ipatasertib + Tecentriq (atezolizumab) in P-Ib Study for 1L Patients with Advanced Triple-Negative Breast Cancer (TNBC)
Shots:
- The P-Ib study involves assessing of Ipatasertib + Tecentriq + CT (paclitaxel/nab-paclitaxel) in 26 patients with locally advanced or metastatic TNBC
- P-Ib study results: ORR 73%; median duration of follow-up 6.1 mos.; Grade ≥3 AEs 54%; all-grade AEs 88%- Presented at AACR 2019
- Ipatasertib is an oral selective AKT inhibitor targeting three isoforms of AKT further blocking the PI3K/AKT signaling pathway and was developed in collaboration with Genentech & Array BioPharma
Ref: Roche | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com